“The development tumor model” to study and monitor the entire progression of both primary and metastatic tumors-Reference-Cited by-同舟云学术

“The development tumor model” to study and monitor the entire progression of both primary and metastatic tumors

Published:2013-11-10 Issue:3 Volume:35 Page:2219-2230
ISSN:1010-4283
Container-title:Tumor Biology
language:en
Short-container-title:Tumor Biol.

Author:

Brognaro Enrico

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s13277-013-1295-9.pdf

Reference57 articles.

1. Brognaro E. A theory and a model to understand glioblastoma development both in the bulk and in the microinfiltrated brain parenchyma. Neurochem Res. 2011;36:2145–54.

2. Brognaro E. How to understand the entire development of the glioblastoma: a theory and an in vivo model. Neuro Oncol. 2012;14(suppl 6):vi160, Abstracts from the 17th SNO Meeting.

3. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist. 2004;9 Suppl 5:10–7.

4. Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist. 2008;13 suppl 3:21–6.

5. Griguer CE, Oliva CR, Gobin E, et al. CD133 is a marker of bioenergetic stress in human glioma. PLoS ONE. 2008;3(11):e3655.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The complex interactions between the cellular and non-cellular components of the brain tumor microenvironmental landscape and their therapeutic implications;Frontiers in Oncology;2022-10-06

2. Effects of matrine in combination with cisplatin on liver cancer;Oncology Letters;2020-11-25

3. Approbation of the Cancer Treatment Approach Based on the Eradication of TAMRA+ Cancer Stem Cells in a Model of Murine Cyclophosphamide Resistant Lymphosarcoma;Anticancer Research;2020-02

4. Glioblastoma Unique Features Drive the Ways for Innovative Therapies in the Trunk-branch Era;Folia Medica;2019-03-31

5. Preclinical imaging and translational animal models of cancer for accelerated clinical implementation of nanotechnologies and macromolecular agents;Journal of Controlled Release;2015-12